Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first‐line antituberculosis drugs: Two case reports and a review of the literature

Coster, Alison; Aerts, Olivier; Herman, Anne; Horst, Niels; Kenyon, Chris; Vlieghe, Erika; Hainaut, Philippe; Baeck, Marie

doi:10.1111/cod.13296

Cited by 18 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite demonstrating an apparent superior safety profile, rifampicin also has the potential to induce severe adverse effects. In addition, rifampicin is frequently associated with drugs interactions that need to be considered when proposing a treatment to LTBI 23–26 . There are several factors that predispose patients to developing anti‐tuberculous drugs‐related hepatotoxicity, such as age above 60 years, low body mass index, female sex, chronic liver disease, alcoholism and HIV infection 23 .…”

Section: Introductionmentioning

confidence: 99%

“…Isoniazid is associated with extensive adverse effects, such as cutaneous and gastro‐intestinal symptoms, peripheral neuropathy and hepatotoxicity. This latter has been highlighted due to several reports of fulminant hepatitis requiring liver transplantation and, in some cases, culminating in the death of the patients 17–25 . Despite demonstrating an apparent superior safety profile, rifampicin also has the potential to induce severe adverse effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change

Nogueira

Warren

Torres

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Tuberculosis is an infectious disease with a major global impact, ranked in the top 10 mortality causes worldwide. In an immunocompetent individual, the host defence mechanisms control Mycobacterium tuberculosis infection and induce the latent form of the disease. However, in the presence of diseases or therapies, which exert an immunosuppressive effect, latent tuberculosis can be re‐activated. Psoriasis is an immune‐mediated, inflammatory disease, and its treatment has rapidly evolved over the last few years. It has long been recognized that the tumour necrosis factor (TNF)‐α inhibitors are associated with increased risk of reactivation of latent tuberculosis infection. Thus, international guidelines have been suggesting tuberculosis screening before starting the treatment with all biological agents since then. In addition, the institution of chemoprophylaxis in the presence of latent tuberculosis and the annual screening for tuberculosis thereafter have also been indicated. However, anti‐tuberculosis treatments can have significant side‐effects and there are currently several contraindications to their use. The risk benefit of starting anti‐tuberculous treatment should be carefully weighed up. The emergence of new biological drugs for the treatment of psoriasis, such as interleukin (IL)‐17 and IL‐23 inhibitors, has reignited the subject of tuberculosis reactivation as it is possible that IL‐17 and 23 blockade do not carry the same risk of TB reactivation as TNF‐α inhibitors. Although preclinical studies have shown that cytokines IL‐17 and IL‐23 have a possible role against infection with M. tuberculosis, data from clinical trials and post‐marketing surveillance with drugs that inhibit these cytokines appear to suggest that they are not crucial to this response. In this article, we review the available data on tuberculosis reactivation after the treatment of psoriasis with IL‐17 and IL‐23 inhibitors, and its possible impact on the way we currently manage latent tuberculosis infection before or after starting treatment with these new drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change

Nogueira

Warren

Torres

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Studies by Husain et al [ 18 ] have shown that drug-induced DIHS may sometimes involve specific organs, such as penicillins, allopurinol, and antiepileptic drugs. ATD is prone to liver injury, including drug direct toxicity and immune-mediated liver injury, that is, hypersensitive liver injury, liver injury caused by lipid peroxidation [ 19 ]. In the reported DIHS caused by ATD, visceral organs are involved extensively and severely, and there is no obvious organ specificity, which can lead to liver damage, polymyositis, myocarditis, pneumonia, and acute renal failure [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs

Xiao

Zong

et al. 2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. To explore the clinical value of the specific plasma cell detection and specific T lymphocyte detection test in diagnosing hypersensitivity caused by antituberculosis drugs. Methods. A total of 266 patients with pulmonary tuberculosis who developed hypersensitivity during the treatment of primary pulmonary tuberculosis in our hospital and 266 patients without hypersensitivity during the treatment of pulmonary tuberculosis in our hospital were selected as the control group. The admission time is from January 2013 to June 2020. The specific plasma cell test and specific T lymphocyte test were used as the criteria to determine which drugs induced hypersensitivity, and the diagnostic value of these two methods in the diagnosis of hypersensitivity induced by four first-line antituberculosis drugs (isoniazid (INH), ethambutol (EMB), rifampicin (RFP), and pyrazinamide (PZA)) was analyzed. Results. The sensitivity of the specific plasma cell test in the diagnosis of hypersensitivity induced by INH, EMB, RFP, and PZA was 63.42%, 51.20%, 47.81%, and 56.37%, respectively, and the specificity was 95.33%, 99.87%, 96.52%, and 99.99%, respectively. The sensitivity of the specific T lymphocyte test in the diagnosis of hypersensitivity induced by INH, EMB, RFP, and PZA was 66.47%, 52.88%, 49.91%, and 58.54%, respectively, and the specificity was 97.28%, 99.99%, 98.38%, and 100.00%, respectively. Conclusion. The specific plasma cell test and specific T lymphocyte test have high specificity in the diagnosis of hypersensitivity caused by antituberculosis drugs, and the specific T lymphocyte test is better than the specific plasma cell test. It is of great significance to guide the clinical application of antituberculosis drugs.

show abstract

“…In a recent systematic review of DRESS syndrome in a pediatric population, the authors found 30 different drugs associated with this disease ( 2 ), but in this review, the antituberculosis medication isoniazid was not included as a causative agent of DRESS ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: DRESS Syndrome Induced by Two Antituberculosis Drugs in an 8-Year-Old Girl

et al. 2022

View full text Add to dashboard Cite

DRESS syndrome is defined as drug-induced hypersensitivity syndrome with rash, eosinophilia, and systemic symptoms. This syndrome is mostly associated with anticonvulsants, antibacterial and anti-inflammatory drugs. DRESS syndrome is a rare disease and is more frequently seen in adults. We present the first case report of DRESS syndrome in an 8-year-old girl, after 3 months of treatment with isoniazid and rifampicin. After discontinuation of drugs and a short course of prednisolone the girl recovered. After 5 years of follow-up, she is healthy and has no complaints but patch tests with isoniazid and rifampicin remain positive. The reported case emphasizes the importance of thorough medical history and including drug reactions in differential diagnosis.

show abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first‐line antituberculosis drugs: Two case reports and a review of the literature

Cited by 18 publications

References 30 publications

Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change

Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs

Case Report: DRESS Syndrome Induced by Two Antituberculosis Drugs in an 8-Year-Old Girl

Contact Info

Product

Resources

About